Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03055897 · ClinicalTrials.gov registry record · NA
Tear Film Innovations iLux Safety Study
A NA study of Meibomian Gland Dysfunction and Evaporative Dry Eye, sponsored by Tear Film Innovations.
- Completed
- Registry status
- NA
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT03055897: Completed NA study of Meibomian Gland Dysfunction and Evaporative Dry Eye, sponsored by Tear Film Innovations.
NCT03055897 is a NA study of Meibomian Gland Dysfunction and Evaporative Dry Eye that has completed, run by Tear Film Innovations. The registered enrollment target is 15 participants, below the 101-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03055897, a NA study of Meibomian Gland Dysfunction and Evaporative Dry Eye, has completed, sponsored by Tear Film Innovations.
- COMPLETED
- Registry status
- NA
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study was to measure the temperature of the cornea and surrounding eye tissue temperature immediately after heating the eyelids with the iLux device using the protocol treatment profile. Eligible participants attended one treatment visit, with follow-up one day following the procedure.
Primary Outcome
Post-heating values were obtained by infrared camera for each participant. The cornea, the eyelid, and the surface tissue surrounding the eye were measured. Both eyes contributed to the analysis. No formal hypothesis testing was specified.
Conditions Studied
Interventions
- DEVICE iLux 2020 System
Study Locations (1)
California
- TearFilm Innovations Investigative Site - Encinitas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2016-05-03 |
| Est. Completion | 2016-05-18 |
| Phase | NA |
What the finished NCT03055897 record still lists
NCT03055897 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 101-participant average among 8 other Meibomian Gland Dysfunction trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Meibomian Gland Dysfunction appearing as the primary indexed condition, and to 1 intervention - of which iLux 2020 System is the first listed.
NCT03055897 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT03055897 about?
NCT03055897 is a clinical study titled "Tear Film Innovations iLux Safety Study". The objective of this study was to measure the temperature of the cornea and surrounding eye tissue temperature immediately after heating the eyelids with the iLux device using the protocol treatment profile. Eligible participants attended one treatment visit, with follow-up one day following the pr...
What is the current status of trial NCT03055897?
This trial is currently completed. It is a NA study. The enrollment target is 15 participants. The study started on 2016-05-03. Estimated completion is 2016-05-18.
What conditions does trial NCT03055897 study?
This clinical trial studies the following conditions: Meibomian Gland Dysfunction, Evaporative Dry Eye.
What interventions are being tested in trial NCT03055897?
The interventions under investigation include: iLux 2020 System (DEVICE).
Who is sponsoring clinical trial NCT03055897?
This trial is sponsored by Tear Film Innovations, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03055897 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Meibomian Gland Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03055897's enrollment target sits among peer trials
15 9th of 8 the lowest of 8 other Meibomian Gland Dysfunction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Meibomian Gland Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Meibomian Gland Dysfunction Management
ACTIVE NOT RECRUITING · NA
-
Clinical Study Evaluating Nordlys™ SWT IPL for Dry Eye Disease (DED) Due to MGD
ACTIVE NOT RECRUITING · NA
-
Comparison Between iLux™ and LipiFlow® in the Treatment of Meibomian Gland Dysfunction
COMPLETED · NA
-
The Efficacy of an Ocular Emulsion in Meibomian Gland Dysfunction
COMPLETED · NA
-
Comparison Between iLux and LipiFlow in the Treatment of Meibomian Gland Dysfunction (MGD): A 12-month, Multicenter Study
COMPLETED · NA
-
Clinical Study Using Eye Lipid Mobilizer (ELM) With Heat and Vibration To Treat Evaporative Dry Eye Disease
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI